Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solifenacin Effect on Bladder Wall Thickness and NGF in Female OAB
NCT01093534Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- Jan 2010
- Primary completion
- Jun 2011
- Modality
- Orthosteric Ligands
- Countries
- 20
01
Overview
A Phase 4 trial of solifenacin in overactive bladder (OAB), sponsored by Astellas Pharma. Started Jan 2010; status: completed.
02
Drugs
solifenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT01093534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01093534.